The EDGE

Spacex Dragon Attached To Space Station In Spaceflight First

2012-05-25T17:52:00.001Z

May 25, 2012

Trent J. Perrotto
Headquarters, Washington
202-358-0321
trent.j.perrotto@nasa.gov

Josh Byerly
Johnson Space Center, Houston
281-483-5111
josh.byerly@nasa.gov

RELEASE: 12-172

SPACEX DRAGON ATTACHED TO SPACE STATION IN SPACEFLIGHT FIRST

HOUSTON -- The International Space Station's Expedition 31 crew
grappled and attached SpaceX's Dragon capsule to the space station
Friday. This is the first time a commercial company has accomplished
this type of space operation.

"Today marks another critical step in the future of American
spaceflight," NASA Administrator Charles Bolden said. "Now that a
U.S. company has proven its ability to resupply the space station, it
opens a new frontier for commercial opportunities in space -- and new
job creation opportunities right here in the U.S. By handing off
space station transportation to the private sector, NASA is freed up
to carry out the really hard work of sending astronauts farther into
the solar system than ever before. The Obama Administration has set
us on an ambitious path forward and the NASA and SpaceX teams are
proving they are up to the task."

Following a series of system tests and a successful fly-under of the
space station Thursday, the Dragon capsule was cleared by NASA to
approach the station Friday. Dragon then performed a series of
intricate test maneuvers as it approached the orbiting laboratory.
These maneuvers were required to demonstrate the maneuvering and
abort capability of Dragon prior to approaching and moving into a
65-foot (20-meter) "berthing box" where it was grappled by NASA
astronaut Don Pettit using the station's robotic arm at 9:56 a.m.
EDT.

European Space Agency astronaut Andre Kuipers installed the capsule on
the bottom of the station's Harmony node at 11:52 a.m. NASA astronaut
Joe Acaba completed berthing operations by bolting the Dragon to
Harmony at 12:02 p.m.

"Congratulations to the SpaceX and NASA teams," said William
Gerstenmaier, associate administrator for NASA's Human Exploration
and Operations Mission Directorate at the agency's headquarters in
Washington. "There is no limit to what can be accomplished with hard
work and preparation. This activity will help the space station reach
its full research potential and open up space-based research to a
larger group of researchers. There is still critical work left in
this test flight. Dragon-attached operations and cargo return are
challenging and yet to be accomplished."

The Dragon capsule lifted off Tuesday from the Cape Canaveral Air
Force Station in Florida aboard a SpaceX Falcon 9 rocket. The
demonstration mission is the second under NASA's Commercial Orbital
Transportation Services program, which provides investments intended
to lead to regular resupply missions to the space station and
stimulate the commercial space industry in America.

"The investments made by the United States to stimulate the commercial
space industry are paying off," said Philip McAlister, director for
Commercial Spaceflight Development at NASA Headquarters. "SpaceX
achieved what until now was only possible by a few governments, and
the company did it with relatively modest funding from the
government.

The Dragon capsule is delivering 1,014 pounds of supplies to the
station, which includes non-critical experiments, food, clothing and
technology. Crew members will open the hatch to the capsule Saturday
and unload the cargo during a four-day period. Dragon then will be
loaded with 1,367 pounds of hardware and cargo no longer needed
aboard the station in preparation for the spacecraft's return to
Earth. Dragon and station hatches will be closed on May 30.

On May 31, the Expedition 31 crew members will detach Dragon from
Harmony, maneuver it to a 33-foot release point and un-grapple the
capsule. Dragon will deorbit approximately four hours after leaving
the station, taking about 30 minutes to re-enter Earth's atmosphere
and landing in the Pacific Ocean about 250 miles west of southern
California.

For up-to-date SpaceX mission information and a schedule of NASA
Television coverage, visit:

http://www.nasa.gov/spacex

For more information about the International Space Station, visit:

http://www.nasa.gov/station

For more information about NASA's commercial space programs, visit:

http://www.nasa.gov/exploration/commercial

-end-

To subscribe to the list, send a message to:
hqnews-subscribe@mediaservices.nasa.gov
To remove your address from the list, send a message to:
hqnews-unsubscribe@mediaservices.nasa.gov

Oncogene - Table of Contents alert Volume 31 Issue 21

2012-05-25T17:39:00.000Z

TABLE OF CONTENTS

Volume 31, Issue 21 (May 2012)

In this issue
Review
Original Articles

Also new
AOP

Nature and Nature Reviews Cancer
WEB FOCUS: CANCER METABOLISM

A renaissance in the field of cancer metabolism has demonstrated links between oncogenic pathways and the mechanistic basis of tumour cell metabolism. This joint Nature and Nature Reviews Cancer Web Focus highlights recent progress in the field and the promise of therapeutics based on interfering with metabolic pathways.

Access the Web Focus at:
www.nature.com/focus/cancermetabolism

Review

Top

Checkpoint control and cancer

R H Medema and L Macůrek

Oncogene 2012 31: 2601-2613; advance online publication, October 3, 2011; 10.1038/onc.2011.451

Abstract | Full Text

Original Articles

Top

CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin–TGFβ signaling

P-K Lo, D Kanojia, X Liu, U P Singh, F G Berger, Q Wang and H Chen

Oncogene 2012 31: 2614-2626; advance online publication, September 26, 2011; 10.1038/onc.2011.439

Abstract | Full Text

Antitumor alkyl-lysophospholipid analog edelfosine induces apoptosis in pancreatic cancer by targeting endoplasmic reticulum

C Gajate, M Matos-da-Silva, E L-H Dakir, R I Fonteriz, J Alvarez and F Mollinedo

Oncogene 2012 31: 2627-2639; advance online publication, November 7, 2011; 10.1038/onc.2011.446

Abstract | Full Text

Somatic LMCD1 mutations promoted cell migration and tumor metastasis in hepatocellular carcinoma

C-Y Chang, S-C Lin, W-H Su, C-M Ho and Y-S Jou

Oncogene 2012 31: 2640-2652; advance online publication, September 26, 2011; 10.1038/onc.2011.440

Abstract | Full Text

Inhibition of β-catenin signaling by nongenomic action of orphan nuclear receptor Nur77

Z Sun, X Cao, M-M Jiang, Y Qiu, H Zhou, L Chen, B Qin, H Wu, F Jiang, J Chen, J Liu, Y Dai, H-F Chen, Q-Y Hu, Z Wu, J-Z Zeng, X-S Yao and X-K Zhang

Oncogene 2012 31: 2653-2667; advance online publication, October 10, 2011; 10.1038/onc.2011.448

Abstract | Full Text

Syntenin-mediated regulation of Sox4 proteasomal degradation modulates transcriptional output

J M Beekman, S J Vervoort, F Dekkers, M E van Vessem, S Vendelbosch, A Brugulat-Panès, J van Loosdregt, A K Braat and P J Coffer

Oncogene 2012 31: 2668-2679; advance online publication, October 10, 2011; 10.1038/onc.2011.445

Abstract | Full Text

Myc, Aurora Kinase A, and mutant p53^R172H co-operate in a mouse model of metastatic skin carcinoma

E C Torchia, C Caulin, S Acin, T Terzian, B J Kubick, N F Box and D R Roop

Oncogene 2012 31: 2680-2690; advance online publication, October 3, 2011; 10.1038/onc.2011.441

Abstract | Full Text

Dynamin 2 mediates PDGFRα-SHP-2-promoted glioblastoma growth and invasion

H Feng, K W Liu, P Guo, P Zhang, T Cheng, M A McNiven, G R Johnson, B Hu and S Y Cheng

Oncogene 2012 31: 2691-2702; advance online publication, September 26, 2011; 10.1038/onc.2011.436

Abstract | Full Text

Nature Genetics and the Wellcome Trust present:
The Genomics of Common Diseases 2012
September 19-22, 2012 - Potomac, MD, USA

For more information and to register, visit:
www.nature.com/natureconferences/gcd2012
Abstract submission deadline- June 28, 2012



		Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com


	More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Oncogene. In order to do so, please purchase a subscription.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.

Blood Cancer Journal - Table of Contents alert Volume 2 May 2012

2012-05-25T17:08:00.000Z

TABLE OF CONTENTS

Volume 2, May 2012

In this issue
Original Articles
Letter to the Editor

Blood Cancer Journal now indexed by Thomson Reuters ISI

We are pleased to inform you that Blood Cancer Journal has been selected for coverage in Thomson Reuter’s products and services and will be indexed and abstracted in:

- Science Citation Index Expanded (also known as SciSearch®)
- Journal Citation Reports/Science Edition
- Current Contents®/Clinical Medicine - Biological Abstracts
- BIOSIS Previews

Original Articles

Top

Role of stromal cell-mediated Notch signaling in CLL resistance to chemotherapy

A H Nwabo Kamdje, G Bassi, L Pacelli, G Malpeli, E Amati, I Nichele, G Pizzolo and M Krampera

Blood Cancer J 2012 2: e73; 10.1038/bcj.2012.17

Abstract | Full Text

Expression of p89^c-Mybex9b, an alternatively spliced form of c-Myb, is required for proliferation and survival of p210BCR/ABL-expressing cells

G Manzotti, S A Mariani, F Corradini, R Bussolari, V Cesi, J Vergalli, G Ferrari-Amorotti, V Fragliasso, A R Soliera, S Cattelani, G Raschellà, T L Holyoake and B Calabretta

Blood Cancer J 2012 2: e71; 10.1038/bcj.2012.16

Abstract | Full Text

Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL

S Mizuta, K Matsuo, T Maeda, T Yujiri, Y Hatta, Y Kimura, Y Ueda, H Kanamori, N Usui, H Akiyama, S Takada, A Yokota, Y Takatsuka, S Tamaki, K Imai, Y Moriuchi, Y Miyazaki, S Ohtake, K Ohnishi and T Naoe

Blood Cancer J 2012 2: e72; 10.1038/bcj.2012.18

Abstract | Full Text

The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML

V Novotny-Diermayr, S Hart, K C Goh, A Cheong, L-C Ong, H Hentze, M K Pasha, R Jayaraman, K Ethirajulu and J M Wood

Blood Cancer J 2012 2: e69; 10.1038/bcj.2012.14

Abstract | Full Text

Letter to the Editor

Top

Does increasing the JAK2V617F assay sensitivity allow to identify more patients with MPN?

E Kouroupi, J-J Kiladjian, C Dosquet, M-L Menot, N Bonnin, L Ades, W Vainchenker, C Chomienne and B Cassinat

Blood Cancer J 2012 2: e70; 10.1038/bcj.2012.15

Full Text

Why choose Blood Cancer Journal for your research?

- Open access
- High visibility
- Fast publication
- High traffic site

For the full Guide to Authors click here

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

The EDGE

Spacex Dragon Attached To Space Station In Spaceflight First

Oncogene - Table of Contents alert Volume 31 Issue 21

Review

Checkpoint control and cancer

Original Articles

CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin–TGFβ signaling

Antitumor alkyl-lysophospholipid analog edelfosine induces apoptosis in pancreatic cancer by targeting endoplasmic reticulum

Somatic LMCD1 mutations promoted cell migration and tumor metastasis in hepatocellular carcinoma

Inhibition of β-catenin signaling by nongenomic action of orphan nuclear receptor Nur77

Syntenin-mediated regulation of Sox4 proteasomal degradation modulates transcriptional output

Myc, Aurora Kinase A, and mutant p53R172H co-operate in a mouse model of metastatic skin carcinoma

Dynamin 2 mediates PDGFRα-SHP-2-promoted glioblastoma growth and invasion

Blood Cancer Journal - Table of Contents alert Volume 2 May 2012

Original Articles

Role of stromal cell-mediated Notch signaling in CLL resistance to chemotherapy

Expression of p89c-Mybex9b, an alternatively spliced form of c-Myb, is required for proliferation and survival of p210BCR/ABL-expressing cells

Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL

The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML

Letter to the Editor

Does increasing the JAK2V617F assay sensitivity allow to identify more patients with MPN?

Myc, Aurora Kinase A, and mutant p53^R172H co-operate in a mouse model of metastatic skin carcinoma

Expression of p89^c-Mybex9b, an alternatively spliced form of c-Myb, is required for proliferation and survival of p210BCR/ABL-expressing cells